ArticleCell and tissue banking2026
Unlocking the surgical potential of Descemet's membrane: a standardized decellularization protocol.
Article in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Corneal Endothelial Progenitors for Ocular Regeneration: Translating Discovery into Clinical Therapies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Descemet's membrane is the specialized extracellular matrix located between corneal stroma and endothelium. This basement membrane provides the biomechanical cues that sustain endothelium viability and function, making it an optimal cell scaffold. The present work describes a new decellularization protocol to remove the cellular components and obtain an acellular scaffold from Descemet's membrane. To induce cell lysis and eliminate all cytoplasmic and nuclear material, Descemet's membranes isolated from donor corneas were subjected to osmotic (hypotonic) shock. The efficiency of the decellularization process was evaluated by the quantification of total residual DNA and analysis by gel electrophoresis. Nuclei removal and extracellular matrix integrity after treatment were verified by histological analysis. In particular, the maintenance of collagen, glycoproteins, perlecan and elastin was analyzed in decellularized tissues compared to untreated controls. DNA quantification showed a 99% reduction of total DNA amount in decellularized Descemet's membranes compared to control ones, with only 28.9 ± 9.86 ng DNA/mg dry tissue residual. Furthermore, the agarose gel electrophoresis and the absence of visible nuclei after decellularization confirmed the efficiency of the process. Histological analyses showed that the composition of the extracellular matrix was not modified by the process. The decellularization protocol is effective in obtaining a Descemet's membrane that is depleted of donor DNA. Furthermore, the treatment preserves tissue matrix components. Descemet's membrane is already prestripped and provided by eye banks; therefore, a decellularized Descemet's membrane represents a valid candidate as a safe scaffold for intraocular surgery as, for example, in the treatment of refractory macular holes.
Indexed as
Identifiers
41569455What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.